Agenda

Preclinical Oncology models-part 1 icon

Tumor Models for Targeted Therapy 

Despite tremendous progress in our understanding of cancer biology, most novel anticancer therapies fail in Phase 3 clinical trials. This situation brings into question the quality of preclinical tumor models and predictability of preclinical trials.  Selection of appropriate animal models based on similarity to human biology/ tumor heterogeneity carries considerable potential to ensure a higher predictability of preclinical trials.

WPC-preclinical-oncology-models-part2

Tumor Models for Cancer Immunotherapy 

The immune system can be programmed to recognize and destroy cancerous cells infected by viruses or affected by transforming genetic or epigenetic alterations. If properly activated, a specific immune attack can lead to a long-term remission or even cure. We are witnessing the renaissance of the concept of immune-mediated cancer therapy, and the need of predictive models for its preclinical assessment is at an all-time high

WPC-functional-screens-safety

Preclinical Drug Safety 

Drug-induced adverse events, particularly organ toxicities, account for most drug recalls and delays experienced in gaining regulatory approvals. So what are pre-clinical safety groups doing to better detect and predict cardiotoxicity, hepatotoxicity, immunogenicity, genotoxicity and other types of toxicities early in drug development? Cambridge Healthtech Institute’s seventh annual conference on Functional Screening for Drug Safety Testing focuses on the most innovative tools, assays, models and biomarkers, that are being used for detecting and predicting idiosyncratic and drug-induced toxicities.

WPC-functional-screens-epigenetic-targets

Epigenetics Screening 

Recent interest in studying epigenetic targets for various therapeutic indications and in probing cellular pathways to find the effects of epigenetic modulation, is driving the need for new tools for epigenetics screening. While the field is still in its infancy, developments on the scientific and technical side are rapidly changing the screening landscape. Most of the work being done focuses on the screening of bromodomains, histone deacetylases, histone demethylases, histone methyltransferases, histone acetyl transferases  and DNA methyl transferases for oncology indications.

WPC-poorly-soluble-drugs

Formulation & Drug Delivery 

Many existing drug compounds as well as those coming out of discovery nowadays are poorly soluble which need special efforts to be formulated into drug products. The second annual conference on Formulation and Drug Delivery will discuss effective formulation and delivery technologies for enhancing solubility and bioavailability. We seek proposals on practical case studies and successful strategies that describe key challenges and solutions in increasing solubility of poorly soluble molecules, maximizing exposure, and opportunities in extending product life cycle.

WPC-process-chemistry

Process Chemistry 

The process chemist in the drug development industry has a difficult job: provide more drug substance material quickly and reliably while also reducing costs of development. Within weeks he/she may have to establish a route to create grams to kilograms of a drug candidate for toxicology tests and clinical trials. Key considerations are controlling impurities such as elemental metals and potential genotoxins. If the drug candidate progresses, the process chemist may focus on the preparation of the optimal final form of the potential active pharmaceutical ingredient (API), and the generation of a practical route that can be used for scale-up to commercial quantities.

WPC-ex-vivo-models

Imaging in Oncology 

Imaging remains an important tool in oncology drug discovery and development. This non-invasive technology delivers significant time and cost reduction when used systematically and skillfully. Cambridge Healthtech’s Fifth Annual Imaging in Preclinical and First in Human Clinical Studies in Oncology is designed to bring together leading imaging experts from industry and academia, as well as scientists who use their services to accelerate cancer research.

WPC-ex-vivo-models

In Vitro Tumor Models 

Predicting whether a potential new anticancer agent will be effective in patients remains a challenge. Murine models, the traditional preclinical hosts for cancer compound testing, have considerable limitations, and scientists are constantly seaching for better technologies for in vitro tumor modeling.  In the last several years considerable progress was made in the area of 3D tissue models as well as novel approaches using cancer cell lines were developed. Cambridge Healthtech Institute’s Inaugural Novel In Vitro Tumor Models conference is designed to present the latest advances in engineering and applications of novel in vitro/ex vivo tumor models.

WPC-CNS-drug-development

Targeting Pain 

Recent market research data shows that the overall world revenue for pain therapeutics will be approximately $68 billion in 2013. With an aging population and increase in prevalence of cancer, diabetes, arthritis and other disorders, the need for pain medications will continue to rise. Hence, it would be interesting to get some insights into what is really happening in the R&D pipeline for pain, as this will drive revenues going forward. Cambridge Healthtech Institute’s seventh annual conference on PAIN: Novel Drug Targets and Screening Tools brings together leading experts, from industry, academia and government/regulatory agencies, to discuss the latest developments and trends in pain research.